Acquisition by Bristol Myers Squibb Mirati Therapeutics' acquisition by Bristol Myers Squibb presents an opportunity for cross-selling products and services to a wider customer base, leveraging the resources and networks of a larger organization.

Financially Healthy With reported revenue between $50M - $100M and substantial funding of $345M, Mirati Therapeutics demonstrates financial stability and potential for significant sales opportunities, indicating capacity for sizable purchases or collaborations.

Competitive Landscape Mirati Therapeutics' similarity with companies like Blueprint Medicines, Deciphera Pharmaceuticals, and Revolution Medicines, with comparable employee size and revenue, hints at a market segment where solutions from these companies may complement each other and lead to strategic partnerships or acquisitions.

Biotechnology Research Focus Being in the biotechnology research industry, Mirati Therapeutics aligns with the current industry trends focused on developing cutting-edge therapies. This industry trend offers potential collaborations, licensing agreements, or joint ventures with other biotech companies aiming to revolutionize cancer treatments.

Technology Utilization Mirati Therapeutics employs various technologies like Google Analytics, Oracle Business Intelligence, and SAP ABAP. Leveraging these tech solutions could provide opportunities for tech integrations or partnerships with other companies in the industry seeking to enhance data analytics or operational efficiencies.